Kotler Kevin
PERIOD 2025-Q4 (filed 2026-02-17) · SOURCE: SEC EDGAR (PUBLIC)
Holdings as of the 2025-Q4 13F-HR filing (filed 2026-02-17). 13F is disclosed up to 45 days after quarter-end.
What a 13F does — and does not — show
These figures come from Form 13F, a quarterly filing that large US institutional managers must submit to the SEC. It is a useful window, but a partial and lagged one, so read it carefully:
- It is a snapshot, up to 45 days old. A 13F shows what a manager held on the last day of a quarter, filed up to 45 days later — the fund may have traded since.
- Long US-listed stocks only. It excludes short positions, cash, bonds, most derivatives, and non-US or private holdings, so it is not the fund’s whole portfolio.
- Reported 13F value is not assets under management. Every share and concentration figure below is a percentage of the reported 13F value only — not the firm’s total assets.
- It describes, it does not recommend. A large or long-held position is not an endorsement, and none of this is investment advice.
Concentration
Share of reported portfolio value. Long US-listed equity positions as filed; percentages are of reported 13F value, which excludes shorts, cash, non-US and private holdings.
| Tier | Reported value | Share |
|---|---|---|
| Top position | $22M | 16.3% |
| Top 5 | $83M | 61.2% |
| Top 10 | $110M | 81.3% |
Top holdings
| # | Security | Shares | Reported value | % of value |
|---|---|---|---|---|
| 1 | ANGO ANGIODYNAMICS INC | 1,713,789 | $22M | 16.3% |
| 2 | AUPH AURINIA PHARMACEUTICALS INC | 1,224,846 | $20M | 14.4% |
| 3 | AVDL AVADEL PHARMACEUTICALS PLC | 741,343 | $16M | 11.8% |
| 4 | OMER OMEROS CORP | 905,635 | $16M | 11.5% |
| 5 | NPCE NEUROPACE INC | 631,468 | $10M | 7.2% |
| 6 | MDWD MEDIWOUND LTD | 337,236 | $6M | 4.6% |
| 7 | AXGN AXOGEN INC | 168,000 | $5M | 4.1% |
| 8 | IART INTEGRA LIFESCIENCES HLDGS C | 427,445 | $5M | 3.9% |
| 9 | ACRS ACLARIS THERAPEUTICS INC | 1,705,929 | $5M | 3.8% |
| 10 | EVTL VERTICAL AEROSPACE LTD | 939,705 | $5M | 3.7% |
| 11 | OSUR ORASURE TECHNOLOGIES INC | 1,801,446 | $4M | 3.2% |
| 12 | LKFT GALAPAGOS NV | 90,000 | $3M | 2.2% |
Sector mix
Reported 13F value by sector, as a share of the largest positions we rank. Sectors come from company reference data joined to each holding. 30% of this value is not classified to a sector and is excluded from the mix. Long US-listed equity positions as filed.
| Sector | Reported value | Share |
|---|---|---|
| Healthcare | $92M | 68.2% |
| Consumer Cyclical | $2M | 1.5% |
How this filer invests
Reproducible measures computed from the positions in this filer’s own 13F filings — not from any outside estimate.
How concentrated the book is
Across 34 reported positions. Shares are of reported 13F value (long US-listed equity), which is not the firm’s total assets. The concentration index (HHI) is the sum of each position’s squared weight — higher means a book concentrated in fewer names.
Frequently asked
What does Kotler Kevin own?
Kotler Kevin reported 34 long US-listed equity positions worth $135M in its 2025-Q4 13F filing.
Where does this data come from?
Holdings are parsed from SEC Form 13F-HR filings on EDGAR (public filings). 13F is disclosed up to 45 days after quarter-end and reflects long US-listed equity positions only. Informational, not investment advice.
About 13F filings
A Form 13F is a quarterly disclosure that institutional investment managers with over $100 million in US-listed equities must file with the SEC. In plain English: it is a snapshot of the long stock positions a fund held at the end of a quarter. It is filed up to 45 days after quarter-end, so it is backward-looking — the manager may have traded since — and it covers long US-listed equities only, not short positions, cash, or private holdings. Reading a 13F tells you what a manager owned, not whether you should own it.